Longevity
Resveratrol is poorly absorbed, and human trials show small, inconsistent metabolic effects — it can even blunt some exercise adaptations. What the trials found and what the red-wine story leaves out.
Key takeaways
Resveratrol gets more press than almost any longevity compound in existence — partly because of a decade of hype around red wine, partly because early mouse studies looked extraordinary, and partly because David Sinclair at Harvard made it a centerpiece of his aging research. But the clinical story is more complicated than the headlines suggest.
Here’s what the evidence actually shows: who resveratrol works for, who it probably doesn’t, the bioavailability problem that undermines most supplement forms, and the emerging data on modified delivery systems that may finally make it clinically relevant.
Resveratrol is a polyphenol — specifically a stilbene — produced by plants under stress. Grapes, blueberries, peanuts, and Japanese knotweed (Fallopia japonica) all synthesize it as a defense against fungal infection and UV radiation.
It comes in two isomeric forms: - trans-resveratrol: the biologically active form - cis-resveratrol: largely inactive, produced when trans-resveratrol is exposed to UV light
Most quality supplements use trans-resveratrol. If your label doesn’t specify, assume a mixed product.
The compound first attracted longevity research attention in 2003 when Howitz et al. showed it activated SIRT1 — a sirtuin protein involved in DNA repair, mitochondrial biogenesis, and metabolic regulation. The popular framing became: resveratrol mimics caloric restriction at the molecular level. That turned out to be partially true and significantly more complicated.
Resveratrol acts through several overlapping pathways, which is both its promise and what makes dose-response relationships difficult to establish.
SIRT1 is a NAD+-dependent deacetylase that regulates transcription factors involved in aging, including FOXO proteins, p53, NF-κB, and PGC-1α. Resveratrol was initially thought to directly activate SIRT1 — a claim that became controversial when Pfizer researchers showed the in vitro assay used fluorescent tags that artificially inflated the apparent activation.
The current understanding: resveratrol likely activates SIRT1 indirectly, through AMPK activation and by raising intracellular NAD+ levels. This is less dramatic than “direct activation,” but the downstream effects on mitochondrial biogenesis and metabolic regulation appear real in humans.
AMP-activated protein kinase (AMPK) is a master energy sensor. When cellular energy is low, AMPK turns on fat oxidation, autophagy, and mitochondrial biogenesis — the same pathways activated by exercise and caloric restriction. Resveratrol activates AMPK both directly (by inhibiting mitochondrial complex I, which raises AMP/ATP ratio) and indirectly via SIRT1.
A 2006 study in Cell (Lagouge et al.) showed resveratrol-supplemented mice on a high-fat diet had 20% greater aerobic capacity, improved mitochondrial function, and protection against metabolic syndrome — all consistent with AMPK activation.
Chronic low-grade inflammation (inflammaging) is a central driver of most age-related disease. Resveratrol consistently inhibits NF-κB nuclear translocation in cell and animal studies, reducing production of TNF-α, IL-6, and IL-1β. Human data are thinner: a 2012 open-label pilot by Crandall et al. (10 older adults with impaired glucose tolerance, 1–2 g/day for 4 weeks, no placebo group) reported better post-meal glucose handling; effects on inflammatory markers across trials are inconsistent and other inflammatory markers significantly vs. placebo.
Resveratrol is often marketed as an antioxidant, but its primary value here is indirect: it upregulates endogenous antioxidant systems (Nrf2/HO-1 pathway) rather than scavenging free radicals directly. This is a more durable mechanism — you’re inducing your own defense systems rather than just adding a dietary antioxidant.
Here’s the issue that undermines most resveratrol research: the compound is absorbed poorly and metabolized extremely fast.
After oral dosing, resveratrol undergoes extensive first-pass metabolism in the intestine and liver. It’s rapidly conjugated to glucuronide and sulfate metabolites, which have lower biological activity than the parent compound. Peak plasma levels of free resveratrol after a 500 mg dose are typically under 40 ng/mL — and the half-life is roughly 1–3 hours.
What does this mean practically? Studies showing beneficial effects in cells often use resveratrol concentrations of 1–100 μM. A typical oral dose achieves maybe 0.01–0.1 μM in peripheral tissues. There’s a 10–100x gap between what works in a petri dish and what you can reliably deliver to tissues with standard supplements.
Several strategies have shown promise:
1. Micronized / Nano-formulated resveratrol Breaking the compound into smaller particles dramatically increases surface area and absorption. A 2011 study found micronized resveratrol (SRT501) reached higher plasma levels than standard resveratrol (Howells et al.); that formulation was later discontinued after kidney injury in a myeloma trial (Popat et al., 2013).
2. Co-administration with piperine Piperine (from black pepper) inhibits glucuronidation enzymes in the intestine, slowing resveratrol’s first-pass clearance. In mice, piperine raised resveratrol exposure by about 229% (Johnson et al., 2011); a human study (Wightman et al., 2014) did not find higher plasma resveratrol with piperine, so the benefit in people is unproven.
3. Quercetin combination Quercetin also inhibits resveratrol sulfation. The two polyphenols are often combined in longevity stacks for this reason — and for their additive effects on SIRT1 and AMPK.
4. Pterostilbene Pterostilbene is a dimethylated analog of resveratrol found in blueberries. It has two methyl groups instead of two hydroxyl groups, which makes it more lipophilic and dramatically improves bioavailability — oral bioavailability in rats of about 80% versus about 20% for resveratrol (Kapetanovic et al., 2011). Some researchers argue pterostilbene is the more practical supplement choice. The trade-off: less clinical trial data, and some concerns that its superior bioavailability also means higher concentrations at doses people actually take.
The strongest human evidence is in metabolic disease. A 2011 study by Timmers et al. (Cell Metabolism) gave 11 obese men resveratrol (150 mg/day × 30 days) in a placebo-controlled crossover design. Results: significant improvements in sleeping metabolic rate, intrahepatic lipid content, glucose tolerance, triglycerides, and mitochondrial markers in muscle biopsies. The effects resembled what you’d expect from caloric restriction. This is one of the more rigorous small trials in the field.
Meta-analyses of small trials in type 2 diabetes report modest reductions in fasting glucose and insulin resistance with high heterogeneity; the 2020 Cochrane review (Jeyaraman et al.) found the evidence insufficient to recommend it., insulin resistance (HOMA-IR −0.79), and HbA1c (−0.39%) in type 2 diabetic patients vs. placebo. Effect sizes are meaningful for metabolic management.
Meta-analyses of small trials are mixed: Liu et al. (2015) found lower systolic blood pressure only at doses of 150 mg/day or more, and Sahebkar et al. (2015) found no significant effect on blood lipids. These effects are modest but consistent.
In laboratory studies resveratrol reduces platelet aggregation; whether this has any clinical effect is untested, though the clinical significance of this specific mechanism needs larger trials.
This is where the data gets more mixed. A 14-week RCT in 80 postmenopausal women (Evans et al., Nutrients 2017; 75 mg twice daily) reported better verbal memory and mood, and the 12-month RESHAW trial (Thaung Zaw et al., 2020, n=125) reported sustained cognitive and cerebrovascular gains — with the effects mediated partly by increased cerebral blood flow. A 2015 phase 2 trial by Turner et al. in mild-to-moderate Alzheimer’s disease (up to 2 g/day for 52 weeks) found it safe and altered a CSF biomarker but did not improve cognition.
Mechanistically, resveratrol crosses the blood-brain barrier and activates SIRT1 in brain tissue. Animal studies consistently show neuroprotective effects. The human brain data is promising but comes from small trials — larger RCTs are needed.
Hundreds of in vitro and animal studies show resveratrol inhibits cancer cell proliferation and induces apoptosis. The clinical evidence is essentially nonexistent at this point. One pilot trial in colorectal cancer patients (Patel et al., 2010) found tissue resveratrol concentrations sufficient to inhibit cell proliferation markers — suggesting the compound can reach tumor tissue — but no therapeutic efficacy data.
Some animal data actually raises concern: very high-dose resveratrol may have pro-oxidant effects in rapidly dividing cells under certain conditions. Do not use resveratrol as a cancer treatment or prevention strategy based on current evidence.
One of the more surprising findings: a 2013 RCT in Journal of Physiology (Gliemann et al.) found resveratrol (250 mg/day) actually blunted the cardiovascular benefits of exercise training in healthy older men — VO2 max, blood pressure, and blood lipid improvements were significantly reduced vs. the placebo group. The proposed mechanism: resveratrol’s antioxidant effects may blunt the reactive oxygen species signaling that drives exercise adaptation.
This doesn’t mean resveratrol is harmful for people who exercise. But it raises a real question: is co-supplementation during intense training counterproductive? Some researchers now suggest cycling resveratrol — not taking it on training days, or taking it only during rest periods. This remains speculative and rests mainly on the single Gliemann trial.
See also SelfHacking’s deep-dive on NAD+ and NMN — resveratrol and NAD+ precursors act on overlapping pathways and are frequently stacked together.
Based on the current trial data, the best-supported use cases for resveratrol are:
| Population | Evidence Level | Primary Benefit |
|---|---|---|
| People with type 2 diabetes | Mixed (small RCTs; Cochrane 2020: insufficient) | Modest glucose/insulin changes in some trials — not a treatment |
| Obese adults / metabolic syndrome | Moderate (RCTs) | Metabolic rate, liver fat, triglycerides |
| Postmenopausal women | Moderate (RCTs) | Cognitive function, cardiovascular markers |
| Older adults (60+) | Moderate | Inflammation, cognitive performance |
| Healthy young adults | Weak | Unclear benefit; possible exercise interference |
Most clinical trials have used 150–1,500 mg/day trans-resveratrol, with the most consistent metabolic effects at 150–500 mg/day. The Timmers et al. metabolic study used 150 mg; the Crandall inflammation study used 1,500 mg. Higher doses don’t clearly produce better outcomes and raise cost and tolerability concerns.
Practical recommendations:
Related compounds to consider: pterostilbene (higher bioavailability, fewer trials), fisetin (overlapping senolytic/SIRT1 effects — see SelfHacking’s Fisetin guide).
Resveratrol has a good safety profile in published trials at doses up to 5,000 mg/day, with most adverse events being mild gastrointestinal (nausea, diarrhea) at higher doses. Doses up to 5 g/day were tolerated for 29 days in healthy volunteers (Brown et al., 2010), but 5 g/day micronized resveratrol caused kidney injury in patients with multiple myeloma and that trial was stopped (Popat et al., 2013) — high doses are not risk-free.
Key interactions and cautions:
Blood thinners: Resveratrol inhibits platelet aggregation and CYP450 enzymes (particularly CYP3A4, CYP2C9, CYP2D6). If you take warfarin, clopidogrel, or other anticoagulants, resveratrol may increase bleeding risk and affect drug metabolism. Discuss with your prescriber before use.
Hormone-sensitive conditions: Resveratrol has weak estrogenic activity (it can bind estrogen receptors). This has been proposed as beneficial for postmenopausal women, but it’s a caution for anyone with hormone-sensitive cancer (breast, uterine, ovarian) or taking hormonal therapies.
Surgery: tell your surgeon you take it; supplements with antiplatelet effects are commonly stopped about two weeks before procedures.
Chemotherapy interactions: Resveratrol inhibits multiple CYP450 enzymes relevant to chemotherapy drug metabolism. Do not use alongside chemotherapy without oncologist supervision.
Thyroid medication: Some evidence that high-dose resveratrol inhibits thyroid peroxidase — relevant for anyone with hypothyroidism on levothyroxine. Low doses (≤150 mg) appear safe; high doses need more study.
See also SelfHacking’s Quercetin and Fisetin articles for the related polyphenol stack context.
Most competitor coverage of resveratrol either (a) leads with the red wine angle and spends half the article explaining why you can’t drink your way to longevity, or (b) retreads the Sinclair/SIRT1 story without engaging the bioavailability problem seriously.
What’s underrepresented in mainstream coverage:
Resveratrol is not the longevity compound the 2006 headlines promised — but it’s not useless either. Small trials in people with type 2 diabetes report modest changes in glucose markers; a 2020 Cochrane review judged the evidence insufficient, and resveratrol is not a treatment for diabetes. Effects on inflammatory markers in human trials are inconsistent. The cognitive data in older women is promising.
The compound is limited by poor bioavailability in standard forms. If you decide to try it, trial doses were 150–500 mg/day taken with food; formulations claiming better absorption have not been shown to change outcomes. And if you’re an active person doing structured training, consider whether timing matters for you based on the Gliemann data.
No trial has tested resveratrol ‘stacks’ for longevity; combining it with NAD+ precursors, fisetin or quercetin is untested and adds interaction risk.
This article is for general education and is not medical advice.
Related
Longevity
The lifting dose linked to longer life is far smaller than a bodybuilding split: pooled cohorts put the lowest mortality at about 30 to 60 minutes of strength work a week, on top of cardio.
Longevity
Many trackers default to 10,000 steps, a figure from a Japanese slogan rather than a trial. Cohort data put the plateau at 6,000 to 8,000 steps a day after 60 and 8,000 to 10,000 before it.
Longevity
NMN and NR both raise blood NAD+ in short human trials; no head-to-head study exists and functional benefits are unproven. Trial doses, safety and what is known about each.
Readers
Comments
Leave a comment